Deals > All

Belgium Luxembourg The Netherlands

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1317 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14

Deal: Collaboration or Financing	Date
Leyden Laboratories–SEVERAL: investment, 202103 financing round Series A €40m led by GV	2021-03-25
Meatable–Agronomics: investment, 202103 financing round Series A totalling $47m incl existing investor Agronomics	2021-03-23
Meatable–BlueYard Capital: investment, 202103 financing round Series A totalling $47m incl existing investor BlueYard Capital	2021-03-23
Meatable–DSM: investment, 202103 financing round Series A totalling $47m incl new investor DSM Venturing	2021-03-23
Meatable–Humboldt Fund: investment, 202103 financing round Series A totalling $47m incl existing investor Humboldt Fund	2021-03-23
Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl existing investor Taavet Hinrikus	2021-03-23
Meatable–PERSON: investment, 202103 financing round Series A totalling $47m incl new investors Rick Klausner + Jeffrey Leiden	2021-03-23
Meatable–Section 32: investment, 202103 financing round Series A totalling $47m incl new investor Section 32	2021-03-23
Meatable–SEVERAL: investment, 202103 financing round Series A $47m from existing + new investors	2021-03-23
Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare	2021-03-17
ExeVir Bio–Noshaq: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Noshaq	2021-03-16
ExeVir Bio–Sambrinvest: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Sambrinvest	2021-03-16
ExeVir Bio–SEVERAL: investment, 202103 financing round Series A extension by €19m + closing at total of €42m	2021-03-16
ExeVir Bio–UCLouvain: investment, 202103 financing round Series A extension totalling €19m incl new + co-investor Vives IUF	2021-03-16
ExeVir Bio–Wallonia (govt): investment, 202103 financing round Series A extension totalling €19m incl new + co-investor SRIW	2021-03-16
AgomAb Therapeutics–Advent France Biotechnology: investment, 202103 financing round Series B totalling $74m incl existing + co-investor AFB	2021-03-10
AgomAb Therapeutics–Andera Partners: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Amdera Partners	2021-03-10
AgomAb Therapeutics–Boehringer: investment, 202103 financing round Series B totalling $74m incl existing + co-investor BIVF	2021-03-10
AgomAb Therapeutics–Cormorant Asset Management: investment, 202103 financing round Series B totalling $74m incl new + co-investor Cormorant	2021-03-10
AgomAb Therapeutics–Omnes Capital: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Omnes Capital	2021-03-10
AgomAb Therapeutics–Pontifax: investment, 202103 financing round Series B totalling $74m incl existing + co-investor Pontifax	2021-03-10
AgomAb Therapeutics–Redmile Group: investment, 202103 financing round Series B totalling $74m incl new + lead investor Redmile Group	2021-03-10
AgomAb Therapeutics–SEVERAL: investment, 202103 financing round Series B $74m led by new investor Redmile Group	2021-03-10
AgomAb Therapeutics–Trophic Communications: public relations, 202103 service existent by Trophic Communications	2021-03-10
AgomAb Therapeutics–V-Bio Ventures: investment, 202103 financing round Series B totalling $74m incl existing + co-investor V-Bio Ventures	2021-03-10
Diagenode–Hologic: investment, 202103 acquisition €130m of Diagenode by Hologic	2021-03-01
Oxular–Forbion: investment, 202103 financing round totalling £27m incl new + lead investor Forbion	2021-03-01
Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion	2021-03-01
Delphi Genetics–Achelous Partners: financial services, 202102 supply service M&A adviser for sale of Delphi Genetics to Catalent	2021-02-23
Delphi Genetics–Catalent: investment, 202102– acquisition 100% valuing Delphi Genetics at $55m	2021-02-23
Delphi Genetics–Osborne Clarke: legal services, 202102 supply service Osborne Clarke Brussels legal adviser to Delphi Genetics on sale Catalent	2021-02-23
Pan Cancer T–Netherlands (govt): grant, 202102 Health~Holland grant for public-private-partnership with Erasmus Medical Center	2021-02-08
Pan Cancer T–SEVERAL: investment, 202102 seed financing round from Swanbridge Capital + Van Herk Ventures	2021-02-08
Pan Cancer T–Swanbridge Capital: investment, 202102 seed financing round incl investor Swanbridge Capital	2021-02-08
Pan Cancer T–Van Herk: investment, 202102 seed financing round incl investor Van Herk Ventures	2021-02-08
Tecan–UgenTec: laboratory automation, 202102– collab product integration of Tecan workstations with FastFinder qPCR-s/w for sale in dx markets	2021-02-04
V-Bio Ventures–SEVERAL: investment, 202102 first closing €78m capital commitments for new V-Bio Ventures Fund 2	2021-02-04
GeneQuine–Noshaq: investment, 202101 financing round Series A totalling €5.4m incl co-investor Noshaq SA	2021-01-26
GeneQuine–SEVERAL: investment, 202101 financing round Series A €5.4m led by Pacira BioSciences	2021-01-26
CureVac–SEVERAL: investment, 202101– follow-on public offering $450m+$67.5m with 5m+750k common shares at $90/share	2021-01-25
Neurent Medical–Life Sciences Partners: investment, 202101 financing round Series B totalling €21m incl lead investor LSP Health Economics Fund 2	2021-01-20
Neurent Medical–SEVERAL: investment, 202101 financing round Series B €21m led by LSP Health Economics Fund 2	2021-01-20
CoviCept Therapeutics–Forbion: investment, 202101 seed investment $2.3 from Forbion	2021-01-19
Merus–SEVERAL: investment, 202101 public offering $120m+$18m with 4.85m+727.3k common shares at $24.75/share	2021-01-19
Novasep–Thermo Fisher: investment, 202101 acquisition €725m in cash of viral vector manufacturing business Henogen SA in Belgium by Thermo Fisher	2021-01-15
NewAmsterdam Pharma–SEVERAL: investment, 202101 financing round Series A €160m co-led by Morningside Ventures + Ascendant BioCapital	2021-01-14
Nile AI–UCB: investment, 202101 majority investment €25m in newly launched Nile AI Inc by UCB	2021-01-13
Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share	2021-01-12
Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based	2021-01-11
Novartis–BeiGene: tisleizumab, 202101– license $650m upfront + royalties + milestones developm + commercialisation in US, CA, MX + Europe + RU + JP	2021-01-11
BioGeneration Ventures–BMS: investment, 202101 final closing of BGV IV totalling €140m incl investor BMS	2021-01-07
BioGeneration Ventures–EU (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor European Investment Fund	2021-01-07
BioGeneration Ventures–Germany (govt): investment, 202101 final closing of BGV IV totalling €140m incl investor KfW Capital	2021-01-07
BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension	2021-01-07
BioGeneration Ventures–Instinctif Partners: public relations, 202101 service existent by Instinctif	2021-01-07
BioGeneration Ventures–Lilly: investment, 202101 final closing of BGV IV totalling €140m incl investor Eli Lilly	2021-01-07
BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures	2021-01-07
BioGeneration Ventures–Schroders: investment, 202101 final closing of BGV IV totalling €140m incl investor Schroder Adveq	2021-01-07
BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al	2021-01-07
Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare	2021-01-05
Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare	2021-01-05
Qiagen–Wellcome Trust: COSMIC Database, 202101– distribution excl rights to license + distribute COSMIC for commercial use	2021-01-01
Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime	2020-12-31
Univercells–Farallon Capital: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Farallon Capital Management	2020-12-17
Univercells–Korea Investment Partners: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor KIP Bio Global Fund	2020-12-17
Univercells–SEVERAL: investment, 202012 financing round Series C 2nd closing €20m with Soros EDF + Farallon Capital et al	2020-12-17
Univercells–Soros Economic Development Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor Soros EDF	2020-12-17
Univercells–TheClubDeal Fund: investment, 202012 financing round Series C 2nd closing totalling €20m incl new investor TheClubDeal Fund	2020-12-17
Locanabio–SEVERAL: investment, 202012 financing round Series B $100m led by Vida Ventures	2020-12-14
Locanabio–UCB: investment, 202012 financing round Series B incl existing + co-investor UCB Ventures	2020-12-14
Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED	2020-12-01
Innatera Nanosystems–btov Partners: investment, 202011 seed financing round totalling €5m incl co-lead investor btov Industrial Technologies Fund	2020-11-25
Innatera Nanosystems–MIG Fonds: investment, 202011 seed financing round totalling €5m incl co-lead investor MIG Verwaltungs AG	2020-11-25
Innatera Nanosystems–SEVERAL: investment, 202011 seed financing round €5m co-lead by MIG Verwaltungs AG + btov Industrial Technologies Fund	2020-11-25
Galapagos–Selvita: drug discovery services, 202011– 202512 supply for 5y by Fidelta after sale by Galapgaos to Selvita	2020-11-23
Galapagos–Selvita: investment, 202011– acquisition 100% of Fidelta d.o.o. for €31.2m in cash by Selvita SA	2020-11-23
Achilles Therapeutics–Forbion: investment, 202011 financing round Series C totalling £52.7m incl existing investor Forbion	2020-11-19
Achilles Therapeutics–SEVERAL: investment, 202011 financing round Series C £52.7m with new + existing investors	2020-11-19
SynOx Therapeutics–Forbion: investment, 202011 financing round Series A totalling €37m incl co-investor Forbion	2020-11-19
SynOx Therapeutics–Gimv: investment, 202011 financing round Series A totalling €37m incl co-investor Gimv	2020-11-19
SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv	2020-11-19
BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent	2020-11-18
DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED	2020-11-18
Pharvaris–Bain Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Bain Capital Life Sciences	2020-11-18
Pharvaris–Cormorant Asset Management: investment, 202011 financing round Series C totalling $80m incl new + co-investor Cormorant Asset Management	2020-11-18
Pharvaris–Foresite Capital: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Foresite Capital	2020-11-18
Pharvaris–General Atlantic: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor General Atlantic	2020-11-18
Pharvaris–Rockefeller: investment, 202011 financing round Series C totalling $80m incl existing + co-investor Venrock Health Capital Partners	2020-11-18
Pharvaris–SEVERAL: investment, 202011 financing round Series C $80m co-led by Viking Global Investors + General Atlantic	2020-11-18
Pharvaris–VenBio: investment, 202011 financing round Series C totalling $80m incl existing + co-investor venBio Partners	2020-11-18
Pharvaris–Viking Global Investors: investment, 202011 financing round Series C totalling $80m incl new + co-lead investor Viking Global Investors	2020-11-18
Lead Pharma–LifeSpring: public relations, 202011 service existent by LifeSpring Communications	2020-11-16
Roche–Lead Pharma: small-molecule immuno modulators, 202011– collab + license agreem up to €260m incl €10m upfront plus royalties	2020-11-16
Apaxen–LifeSpring: public relations, 202011 service existent by LifeSpring Life Sciences Communications	2020-11-12
Handl Therapeutics–UCB: investment, 202011 acquisition of Handl Therapeutics by UCB	2020-11-12
Catalym–SEVERAL: investment, 202011 financing round Series B €50m led by Vesalius Biocapital III	2020-11-10
Catalym–Vesalius Biocapital: investment, 202011 financing round Series B totalling €50m incl lead investor Vesalius Biocapital III	2020-11-10
The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings	2020-11-03
Eurofins–Waters: mass spectrometer, 202011 supply existent Radian ASAP System beta customer Eurofins Forenscis Teddington	2020-11-02
Fountain Healthcare Partners–Kyowa Kirin: investment, 202011 final closing of Fund III totalling addit €7m incl new investor Kyowa Kirin Co Ltd	2020-11-02

1 2 3 4 5 6 7 8 9 10 11 12 13 14

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)